As with many emerging biotech companies, shares in UK-based Verona Pharma have jumped around a fair bit as markets make their predictions on whether their leadi 29 October 2017
Nobody is surprised now when pharma companies that are presenting data at scientific conferences choose to focus on real-world evidence (RWE) as much as, or mor 20 October 2017
While the pharmaceutical industry is often regarded as being sluggardly in its embrace of change, opportunities in digital technology appear to be on the rise, 3 October 2017
The European Commission (EC) approval of a combination involving Kisqali (ribociclib) for a large breast cancer indication last month led a senior executive fro 27 September 2017
As competition in immuno-oncology hots up, in New York, a biotech startup called Rgenix has entered the fray with RGX-104, a small molecule currently entering P 8 September 2017
Antony Odell, chief executive of UK-based regenerative medicine company Tissue Regenix, is honest about the industry’s mixed fortunes so far when it comes to tu 25 August 2017
San Franciscan firm Cytokinetics is pursuing an unusual angle to therapeutic discovery, starting from an understanding of the biology of muscles in order to exp 22 August 2017
With the approval of Vosevi (sofosbuvir/velpatasvir/voxilaprevir) in the USA and Europe last month, US biotech giant Gilead Sciences has now brought to market f 16 August 2017
As the recent G20 Summit kicked off, in the midst of unprecedented civil unrest, advocates and lobbyists of every stripe descended on Hamburg in an effort to pu 10 August 2017
While researchers have long tangled over the pathology of Alzheimer’s disease, recent trial failures have renewed interest in tau proteins as a therapeutic targ 26 July 2017
The fall of solanezumab late last year, followed by verubecestat in February, sent tremors through the Alzheimer's research community and wiped billions from th 24 July 2017
The perception that biomarkers will be key to unlocking the potential of precision medicine is so popular that they are now seen as an essential part of the dru 21 July 2017
As a lifelong follower of the so-called ‘tau hypothesis’, TauRx Therapeutics chief executive Claude Wischik ploughed a lonely furrow for many years. 18 July 2017
Biopharmaceutical research draws from a diffuse range of highly specialized technologies, and the traditional wisdom is that pharmaceutical firms, even very lar 4 July 2017
With EULAR in full swing in Madrid, much of the focus, as in other therapeutic areas, has been on the use of biomarkers to guide personalized treatment options. 16 June 2017
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.